Goldman Sachs’s Elicio Therapeutics ELTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$103K Buy
+56,677
New +$157K ﹤0.01% 6340
2026
Q2
– Sell
-57,818
Closed -$618K – 6690
2026
Q1
$618K Buy
+57,818
New +$558K ﹤0.01% 5463

Other funds holding ELTX

Goldman Sachs's ELTX Position: Q3 2026 in Review

Goldman Sachs opened a new position in Elicio Therapeutics (ELTX) in Q3 2026: 56,677 shares worth $103K. The stake represents ﹤0.01% of the portfolio and ranks #6340 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in ELTX as recently as Q1 2026.

Goldman Sachs first reported a position in ELTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $618K in Q1 2026. 78 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Goldman Sachs held 56,677 shares of Elicio Therapeutics worth $103K as of Q3 2026.
  • Elicio Therapeutics was a new Goldman Sachs position in Q3 2026.
  • Elicio Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #6340 holding.
  • Goldman Sachs first reported a position in Elicio Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Goldman Sachs's Elicio Therapeutics position peaked at $618K in Q1 2026.
  • 78 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.